Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II/Pharmacodynamic Study of the γ-secretase Inhibitor RO4929097 in Patients Who Have Recently Completed Front-Line Chemotherapy for Advanced Non-small Cell Lung Cancer

NCT01193868 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01193868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01193868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II/Pharmacodynamic Study of the γ-secretase Inhibitor RO4929097 in Patients Who Have Recently Completed Front-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2010
Completion date
April 30, 2014
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent non-small cell lung cancer, stage iiib non-small cell lung cancer, stage iv non-small cell lung cancer